Access to Tempus's de-identified multimodal oncology patient records for drug discovery, five-year licence to Recursion
annual license fees ranging between $22.0 million and $42.0 million per year of a five-year term (up to $160.0 million in total)
Dated Nov 2023Source checked 14 Oct 2026Quote found on its page again 17 Oct 2026Basis: stated
In the source's own words
“the Company paid Tempus an initial license fee in an amount equal to $22.0 million, or the Initial License Fee and agreed to pay annual license fees during the Term ranging between $22.0 million and $42.0 million, which, together with the Initial License Fee, totals up to $160.0 million over the Term”
Where it was read
What it is about
Figures it counts in
- $30.4M per contract yearImages, sales that happened, per contract year
Cited in this guide